High-performance proteins at the speed of mRNA.
Boost's Rapid Antigen Deployment (RAD™) pathogen-family-specific platforms allow us to rapidly create protein antigens, vaccines, and monoclonal antibodies against globally important pathogens.
Our proteins are engineered to be safe, effective, quickly scalable for population-wide rapid response, low-cost, stable, and updatable. Terminal sterilization and intranasal administration are possible.
Our lead SARS-CoV-2 program is in Phase 1, with data mid-2026.
Backed by the Best
The world's leading pandemic preparedness and biomedical research institutions — including the Coalition for Epidemic Preparedness Innovations (CEPI), the National Institutes of Health / National Institute of Allergy and Infectious Disease (NIH/NIAID), and the Center for the Biomedical Advanced Research and Development Authority (BARDA) — support Boost’s work developing new vaccines and monoclonal antibodies.
The company is also supported by dedicated and knowledgable investors.
We're building a company that responds to global health needs with safety, efficacy, speed, and cost in mind. If that's a vision you share — as an investor, partner, or collaborator — let's talk.